Breaking News Instant updates and real-time market news.

TNDM

TNDM

, ABT

Abbott

$72.86

-3.37 (-4.42%)

09:14
04/18/19
04/18
09:14
04/18/19
09:14

Investors should buy into Tandem Diabetes 'fire sale,' says Lake Street

Lake Street analyst Brooks O'Neil attributes the recent selloff in shares of Tandem Diabetes (TNDM) to investor fears related to the potential implications of "Medicare For All." Yesterday, the decline also appeared to "draw fuel from the strong growth" Abbott (ABT) reported for its Libre glucose monitor for diabetics, O'Neil tells investors in a research note titled "Fire Sale. Should You Buy? Yes. There Is No Fire. Affirm BUY, $100 PT." The analyst doubts the healthcare system will be changed significantly and on Libre, he says, "We're sorry, but we believe investors are either badly confused or just plain wrong." Abbott offers a low-cost version of the monitoring system but does not compete in any way with Tandem in its pump market, says the analyst. Rather, O'Neil thinks there are "potentially significant positives" for Tandem Diabetes related to the "enormous success" of Abbott's Libre franchise. The analyst sees an "extraordinarily positive" outlook for Tandem Diabetes and recommends buying the shares on the recent pullback. He affirms a Buy rating on the shares with a $100 price target.

TNDM

TNDM

ABT

Abbott

$72.86

-3.37 (-4.42%)

  • 24

    Apr

  • 26

    Apr

  • 30

    Apr

  • 30

    Apr

  • 06

    May

  • 08

    May

  • 08

    May

  • 09

    May

TNDM TNDM

03/06/19
LSCM
03/06/19
NO CHANGE
Target $100
LSCM
Buy
Tandem Diabetes business 'is just getting going,' says Lake Street
While the shares of Tandem Diabetes have had a nice move, the business is "just getting going," Lake Street analyst Brooks O'Neil tells investors in a research note partially titled "Why $100 And How Fast?" The analyst believes Tandem has the best pump on the market today coupled with a pipeline of future products "that will bring market leading innovation to diabetics world-wide over the next few years." He sees the shares going to $100 and affirms a Buy rating on Tandem Diabetes.
03/06/19
BARD
03/06/19
NO CHANGE
Target $65
BARD
Outperform
Tandem Diabetes trial 'hiccup' can be fixed quickly and easily, says Baird
After speaking with management at Tandem Diabetes, Baird analyst Jeff Johnson said his understanding is that the software bug the company announced in its Control-IQ clinical trial is small, has not impacted a single patient, and is easy to fix. The issue may not delay the launch of Control-IQ at all, or if it does it would be by a couple to a few weeks at most, added Johnson, who views today's news as "nothing more than a small hiccup." The analyst, who thinks the 5% selloff in Tandem shares appears overdone, keeps an Outperform rating and $65 price target on the stock.
03/06/19
PIPR
03/06/19
NO CHANGE
Target $67
PIPR
Overweight
Tandem Diabetes' software change likely only 2-3 week delay, says Piper Jaffray
After talking with Tandem Diabetes' management following the press release involving a software update to Control-IQ mid-trial, Piper Jaffray analyst JP McKim says the company does not expect this update to delay any of the key timelines including trial data at ADA or the Control-IQ launch later this year. The analyst's base case is that this delays the trial end date by 2-3 weeks, which in the grand scheme of things is "not a big deal." Early feedback from patients and physicians is that Control-IQ is "a game changer," so with 71% of patients in the trial already complete, McKim does not expect this to impact the data or adoption in a negative way. He reiterates an Overweight rating and $67 price target on the shares.
03/08/19
BMOC
03/08/19
INITIATION
Target $77
BMOC
Outperform
Tandem Diabetes initiated with an Outperform at BMO Capital
BMO Capital analyst Joanne Wuensch started Tandem Diabetes with an Outperform rating and $77 price target. Manufacturers are consolidating as pump utilization is increasing and Tandem's product pipeline is differentiated, Wuensch tells investors in a research note. Further, the company's momentum "is evident" as its Q4 revenue increased 91% year-over-year and its and gross margins rose 1,060 basis points, adds the analyst. Over time, Wuensch expects more of the 3.3M U.S. insulin-dependent patients to migrate to pumps.
ABT Abbott
$72.86

-3.37 (-4.42%)

03/22/19
BMOC
03/22/19
NO CHANGE
Target $204
BMOC
Outperform
Edwards Lifesciences price target raised to $204 from $190 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Edwards Lifesciences (EW) to $204 and kept her Outperform rating while removing the stock from her Top Picks list after its 25% year-to-date run-up. While there are some mid-year catalysts for the company such as the outcomes from the CMS NationalCoverage Decision proposal on March 27, clinical data from Pascal, and patent litigation with Abbott (ABT) regarding Pascal, the analyst contends that some consolidation in the stock price would not be surprising.
03/26/19
PIPR
03/26/19
NO CHANGE
Target $165
PIPR
Overweight
Piper discusses 16% selloff in DexCom over past three trading days
Piper Jaffray analyst JP McKim says he's fielded a lot of investor questions with shares of DexCom (DXCM) down 16% over the last three trading days. The crux of the selloff is Abbott's (ABT) Libre 2.0 and whether it gets interoperable continuous glucose monitoring and if so, what that does to volumes and price, McKim tells investors in a research note. The analyst sees little risk to DexCom's volumes for given the market inflection for continuous glucose monitoring, but adds that if Libre gets iCGM "payers maybe push a little harder on price." McKim admits that "headline risk is building around the approval" but keeps an Overweight rating on DexCom shares with a $165 price target. Libre 2.0 getting iCGM is not fully priced in the stock at this point, but some of that risk certainly is, says McKim.
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".

TODAY'S FREE FLY STORIES

TRVN

Trevena

$0.72

-0.0001 (-0.01%)

07:07
12/12/19
12/12
07:07
12/12/19
07:07
Hot Stocks
Trevena presents Phase 1 data on TRV250 for acute migraine »

Trevena announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$46.22

-0.615 (-1.31%)

07:07
12/12/19
12/12
07:07
12/12/19
07:07
Hot Stocks
Rexford Industrial acquires two industrial properties for $99.7M »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$114.70

4.61 (4.19%)

07:07
12/12/19
12/12
07:07
12/12/19
07:07
Earnings
Asbury Auto sees Park Place acquisition accretive to 2020 EPS by $1.00-$1.25 »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$314.32

0.77 (0.25%)

, SPX

S&P 500

$0.00

(0.00%)

07:06
12/12/19
12/12
07:06
12/12/19
07:06
Periodicals
White House to have 'high-stakes' meeting today on China tariffs, Reuters says »

President Donald Trump is…

SPY

SPDR S&P 500 ETF Trust

$314.32

0.77 (0.25%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$14.49

0.05 (0.35%)

07:06
12/12/19
12/12
07:06
12/12/19
07:06
Earnings
Lovesac narrows FY20 revenue growth view 40%-42% from 40%-45% »

Consensus $238.38M. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

EVH

Evolent Health

$8.26

-0.73 (-8.12%)

07:05
12/12/19
12/12
07:05
12/12/19
07:05
Recommendations
Evolent Health analyst commentary  »

Evolent partner could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$8.26

-0.73 (-8.12%)

07:05
12/12/19
12/12
07:05
12/12/19
07:05
Recommendations
Evolent Health analyst commentary  »

Evolent partner could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$114.70

4.61 (4.19%)

07:05
12/12/19
12/12
07:05
12/12/19
07:05
Hot Stocks
Asbury Automotive to acquire assets of Park Place Dealerships for $1B in cash »

Asbury Automotive entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$73.77

0.99 (1.36%)

07:04
12/12/19
12/12
07:04
12/12/19
07:04
Recommendations
NuVasive analyst commentary  »

NuVasive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.25

0.05 (4.17%)

07:04
12/12/19
12/12
07:04
12/12/19
07:04
Hot Stocks
Soligenix initiates clinical trial of heat stable ricin toxin vaccine »

Soligenix has opened a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$35.45

0.75 (2.16%)

07:04
12/12/19
12/12
07:04
12/12/19
07:04
Earnings
Ciena reports Q4 adj. EPS 58c, consensus 63c »

Reports Q4 revenue $968M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

LOVE

Lovesac

$14.49

0.05 (0.35%)

07:03
12/12/19
12/12
07:03
12/12/19
07:03
Earnings
Lovesac reports Q3 adjusted EPS (46c), consensus (43c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

  • 19

    Dec

UBX

Unity Biotechnology

$7.69

-0.37 (-4.59%)

07:03
12/12/19
12/12
07:03
12/12/19
07:03
Conference/Events
Unity Biotechnology management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CGC

Canopy Growth

$20.30

0.21 (1.05%)

07:03
12/12/19
12/12
07:03
12/12/19
07:03
Hot Stocks
Canopy Growth announces launch of 'First & Free' product line »

Canopy Growth announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$11.28

-0.34 (-2.93%)

07:02
12/12/19
12/12
07:02
12/12/19
07:02
Hot Stocks
Provention Bio backs regulatory guidance for PRV-031 »

Provention Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$167.44

1.69 (1.02%)

07:02
12/12/19
12/12
07:02
12/12/19
07:02
Hot Stocks
Nordson announces planned retirement of CFO Gregory Thaxton »

Nordson announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

LCI

Lannett

$8.79

-0.085 (-0.96%)

07:02
12/12/19
12/12
07:02
12/12/19
07:02
Hot Stocks
Lannett to commence marketing for generic Adderall XR in coming months »

Lannett announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$122.38

0.14 (0.11%)

07:01
12/12/19
12/12
07:01
12/12/19
07:01
Conference/Events
Take-Two management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

AMRX

Amneal Pharmaceuticals

$3.49

-0.015 (-0.43%)

07:01
12/12/19
12/12
07:01
12/12/19
07:01
Hot Stocks
Amneal Pharmaceuticals' EluRyng Abbreviated New Drug Application approved »

Amneal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$147.08

1.89 (1.30%)

07:01
12/12/19
12/12
07:01
12/12/19
07:01
Recommendations
Zimmer Biomet analyst commentary  »

Zimmer Biomet price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:00
12/12/19
12/12
07:00
12/12/19
07:00
General news
European stock markets are mostly higher, »

European stock markets…

DAN

Dana

$18.01

0.55 (3.15%)

07:00
12/12/19
12/12
07:00
12/12/19
07:00
Hot Stocks
Dana extends share repurchase program »

Dana announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco

$60.91

0.34 (0.56%)

06:59
12/12/19
12/12
06:59
12/12/19
06:59
Conference/Events
Sonoco management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PWR

Quanta Services

$40.21

0.3 (0.75%)

06:58
12/12/19
12/12
06:58
12/12/19
06:58
Hot Stocks
Quanta Services increases quarterly dividend to 5c per share »

Quanta Services announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$574.82

-0.33 (-0.06%)

06:58
12/12/19
12/12
06:58
12/12/19
06:58
Recommendations
Intuitive Surgical analyst commentary  »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.